Antifungal antibiotics and breakthrough bacteremias.
Antifungal antibiotics and breakthrough bacteremias.
复制标题
抗真菌抗生素和突破性菌血症。
DOI：
10.1086/320534
复制
发表时间：
2001
影响因子：
11.8
通讯作者：
Michael B. Edmond
中科院分区：
文献类型：
--
作者：
Richard P. Wenzel;Chris Gennings;Michael B. Edmond
发热和中性粒细胞减少的患者感染（约50%）和菌血症（约20%）的风险较高。因此，大多数人接受抗菌预防治疗，直到他们的绝对中性粒细胞计数超过500个细胞/mm（3），他们的体温恢复正常。美国传染病学会1997年的指南建议了3种治疗方案中的一种：万古霉素加头孢他啶，头孢他啶或亚胺培南（可能是头孢吡肟或美罗培南）单药治疗，或氨基糖苷类药物加抗假单胞菌β-内酰胺的双重治疗。
Patients with fever and neutropenia are at high risk for infection ( approximately 50%) and bacteremia ( approximately 20%). As a result, most are treated with antibacterial prophylaxis until their absolute neutrophil count exceeds 500 cells/mm(3) and their temperature returns to normal. The 1997 guidelines of the Infectious Diseases Society of America suggested 1 of 3 regimens: vancomycin plus ceftazidime, monotherapy with ceftazidime or imipenem (possibly cefepime or meropenem), or dual therapy with an aminoglycoside plus an antipseudomonal beta-lactam.